Chris Ogden
Chief Financial Officer
Replay available
CytomX Therapeutics, Inc. (CTMX) Q1 2025 Earnings Call
CytomX Therapeutics, Inc. (NASDAQ: CTMX) Q1 2025 earnings conference call, held 2025-05-13. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Sean McCarthy
Chief Executive Officer & Chairman
Dr. Wayne Chu
Chief Medical Officer
Roger Song
Analyst, Jefferies
Anupam Rama
Analyst, J.P. Morgan
Peter Lawson
Analyst, Barclays
Robert Driscoll
Analyst, Wedbush
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Cytomx Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:03.134 Good morning, everyone, and thank you for standing by. 00:00:03.134 -- 00:00:07.298 Welcome to the CitumX Therapeutics CX2051 00:00:07.298 -- 00:00:12.303 Phase 1 Interim Clinical Data Call. Please be advised that today's call is being 00:00:12.303 -- 00:00:17.128 recorded. I would now like to hand the call over to your host for today, Chris Ogden, 00:00:17.128 -- 00:00:21.690 CitumX's Chief Financial Officer. Please go ahead. 00:00:23.714 -- 00:00:27.158 Thank you. Good morning, and thank you for joining us. 00:00:27.158 -- 00:00:31.542 Before we begin, I would like to remind everyone that during this call we were making 00:00:31.542 -- 00:00:36.107 forward-looking statements. Because forward-looking statements relate to the future, 00:00:36.107 -- 00:00:41.833 they're subject to inherent uncertainties and risks that are difficult to predict 00:00:41.833 -- 00:00:45.397 and many of which are outside of our control. 00:00:45.397 -- 00:00:51.283 Important risks and uncertainties are set forth in our most recent public filing 00:00:51.283 -- 00:00:54.687 with the SEC at sec.gov. 00:00:54.687 -- 00:01:00.410 We undertake no obligation to update any forward-looking statements whether as a result 00:01:00.410 -- 00:01:05.398 of new information, future developments, or otherwise. 00:01:05.398 -- 00:01:10.205 Earlier today, we issued a press release that includes a summary of our first quarter 00:01:10.205 -- 00:01:12.649 2025 financial 00:01:12.649 -- 00:01:16.575 results and highlights recent progress at Cytomix. 00:01:16.575 -- 00:01:21.782 Additionally, this morning, we are excited to announce both positive interim phase 00:01:21.782 -- 00:01:27.231 one data for CX2051 and advanced colorectal cancer, 00:01:27.231 -- 00:01:32.625 as we...